A novel multiple marker assay that uses serum HE4 and CA125 to calculate a risk of ovarian malignancy algorithm better predicts epithelial ovarian cancer in women with pelvic masses than the risk of malignancy index, according to recent research.
A novel multiple marker assay that uses serum HE4 and CA125 to calculate a Risk of Ovarian Malignancy Algorithm (ROMA) better predicts epithelial ovarian cancer in women with pelvic masses than the Risk of Malignancy Index (RMI), according to recently published research.
Researchers included in their study 457 women with an identified pelvic mass or ovarian cyst and planned surgical intervention. They determined RMI values using CA125, imaging score, and menopausal status and established ROMA values using HE4, CA125, and menopausal status.
The researchers found that the sensitivity for distinguishing benign masses from cancerous lesions was 94.3% for ROMA and 84.6% for RMI (P=.0029) at a set specificity of 75%. For women with stage I or II disease, sensitivities were 85.3% and 64.7%, respectively (P<.0001).
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More